Solventum Corporation has completed the acquisition of Acera Surgical, a bioscience company specializing in fully engineered materials for regenerative wound care. This move expands Solventum’s MedSurg portfolio into the rapidly growing synthetic tissue matrices technology segment, particularly in acute care settings in the U.S. Acera is projected to generate approximately $90 million in sales in 2025. The transaction is expected to have an immaterial impact on Solventum’s financial results for the fourth quarter of 2025, be slightly dilutive to adjusted earnings per share in 2026, and accretive beginning in 2027.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Solventum Corporation published the original content used to generate this news brief via PR Newswire (Ref. ID: CG52916) on December 23, 2025, and is solely responsible for the information contained therein.